Dodge & Cox’s Alexion Pharmaceuticals ALXN Stock Holding History

Dodge & Cox’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,820	Closed	-$253K	–	191
2016 Q1	$253K	Buy	+1,820	New	+$267K	﹤0.01%	182

Other funds holding ALXN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox's ALXN Position: Q2 2016 in Review

Dodge & Cox sold out of Alexion Pharmaceuticals (ALXN) in Q2 2016, closing a stake of 1,820 shares — an estimated $253K sold.

Dodge & Cox first reported a position in ALXN in Q1 2016 and held it in 1 quarter. The position peaked at $253K in Q1 2016. 534 funds tracked by Wall St. Rank hold ALXN as of Q2 2016.

Dodge & Cox reported no remaining Alexion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Dodge & Cox sold 1,820 Alexion Pharmaceuticals shares in Q2 2016, an estimated $253K.
Dodge & Cox first reported a position in Alexion Pharmaceuticals in Q1 2016 and held it in 1 quarter.
Dodge & Cox's Alexion Pharmaceuticals position peaked at $253K in Q1 2016.
534 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2016.

Based on Dodge & Cox's 13F filing for Q2 2016, filed 12 Aug 2016.